HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.1
  1. Home
  2. /Compound

Flecainide

HCID 3356
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
54143-55-4
Standard SMILES
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
Molecular formula
C17H20F6N2O3
Average molar mass
414.34 g/mol
Monoisotopic mass
414.13781148

Overview

Flecainide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). It has a role as an anti-arrhythmia drug. It is a member of piperidines, a monocarboxylic acid amide, an aromatic ether and an organofluorine compound. It is a conjugate base of a flecainide(1+).

Names & identifiers

Preferred name
Flecainide
IUPAC
N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
English name
Flecainide
Molecular formula
C17H20F6N2O3
Molecular weight
414.34

Names & synonyms

flecainide54143-55-4FlecaineN-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideFlecainidaFlecainidum(+-)-FlecainideN-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideCCRIS 313Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-DTXSID8023054NSC-719273
Show more names
Flecainide-d4Flecaniderac FlecainideFLECAINTDE BASEFlecainide USP/EP/BP(±)-Flecainide solution(±)-Flecainide solutionN-(Piperidin-2-ylmethyl)
K94FTS1806DTXCID403054CHEBI:75984THN-102 COMPONENT FLECAINIDEFlecainid IsisRefChem:56566C01BC04685-650-9

Database identifiers

CAS
54143-55-4、54143-56-5

Properties

Computed structural propertiesFilling in

XLogP
3.8
Topological polar surface area
59.6 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
10
Rotatable bonds
7
Heavy atoms
28
Formal charge
0
Complexity
500

Experimental & physicochemical properties

PFASPFAS -> PFAS identified in REACH Regulation EC No. 1272/2008
Drugs · 3 items

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Cardiovascular system -> Cardiac therapy

LogP · 2 items

4.6

3.78

Solubility3.24e-02 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antiarrhythmics

Pharmaceuticals

Melting Point228-229
Physical DescriptionSolid
Dissociation Constants · 2 items

9.3

9.3

Collision Cross Section192.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationREACH registered substance: N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide (EC: 685-650-9)
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Treatment · 1 item

Treatment of flecainide toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent, and administration of a sodium load (often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily obviate the need for a beating heart and to increase blood flow to the liver. (L1129)

Health Effects · 1 item

Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. There may be signs and symptoms attributable to overt heart failure secondary to sudden decreased myocardial contractility (L1129).

Hepatotoxicity

Chemistry & industry

Pharmacology

ATC Code · 3 items

C01BC04

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingFlecainide is 40% bound to protein in serum, mainly to alpha-1-acid glycoprotein and minorly to serum albumin.
Pharmacodynamics · 1 item

Flecainide inhibits the action of sodium and potassium ion channels in the heart, raising the threshold for depolarization and correcting arrhythmias. Flecainide has a long duration of action, allowing for once daily dosing. The therapeutic index is narrow. Patients should not take this medication if there is already structural heart disease or left ventricular systolic dysfunction.

Mechanism of Action · 1 item

Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart. This blockade also shortens the duration of action potentials through the Purkinjie fibers. Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers. Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.

Biological Half-Life · 1 item

In healthy subjects, intravenous flecainide has an average half life of 13 hours for a single dose and 16 hours for multiple oral doses. In patients with a ventricular premature complex, flecainide has a half life of 20 hours. The half life of meta-O-dealkylated flecainide, a major metabolite of flecainide, is 12.6h.

Metabolism/Metabolites · 2 items

Flecainide is mainly metabolized to meta-O-dealkylated flecainide or the meta-O-dealkylated lactam of flecainide. Meta-O-dealkylated flecainide has 20% the activity of flecainide. Both of these metabolites are generally detected as glucuronide or sulfate conjugates. Flecainide’s metabolism involves the action of CYP2D6 and CYP1A2.

Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). The absoprtion is nearly complete following oral administration. Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite). Route of Elimination: In healthy subjects, about 30% of a single oral dose (range, 10 to 50%) is excreted in urine as unchanged drug. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 ug/mL). Half Life: 20 hours (range 12-27 hours)

Related reactions

14 records
New reaction record
HRID 460428 reaction equation
HRID 460428As productuspto-grants-2007_03
HRID 460429 reaction equation
HRID 460429As reactantuspto-grants-2007_03
HRID 838420 reaction equation
HRID 838420As productTest data from https://doi.org/10.1039/C8SC04228D
HRID 959705 reaction equation
HRID 959705As reactantValidation data from https://doi.org/10.1039/C8SC04228D
HRID 1138736 reaction equation
HRID 1138736As reactantTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1359120 reaction equation
HRID 1359120As reactantuspto-grants-2003_07
HRID 1359121 reaction equation
HRID 1359121As productuspto-grants-2003_07
HRID 2290621 reaction equation
HRID 2290621As reactantuspto-grants-1986_10
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
PubChem CID
3356
DTXSID
DTXSID8023054
ChEMBL
CHEMBL652
ChEBI
CHEBI:75984
UNII
K94FTS1806
EC Number
685-650-9、923-247-4
Nikkaji
J12.413C、J399.064H、J399.065F

Physicochemical properties

Melting point
105 · 105-1070C
Boiling point
434.9 · 434.9±45.0 °C(Predicted)
Density
1.286 · 1.286±0.06 g/cm3(Predicted)
Flash point
9 ℃ · 9℃
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
Chloroform (Slightly), Methanol (Slightly)
form
Solid
pka
9.3 · pKa 9.3 (Uncertain)
color
White to Off-White
BCS Class
1 or · 1 or 2
Major Application
clinical testing
InChI
1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChIKey
DJBNUMBKLMJRSA-UHFFFAOYSA-N
SMILES
O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F
CAS DataBase Reference
54143 · 54143-55-4(CAS DataBase Reference)
EWG's Food Scores
1 · 1
NCI Dictionary of Cancer Terms
flecainide
FDA UNII
94 FTS1806 · K94FTS1806
ATC code
1 BC04 · C01BC04
NIST Chemistry Reference
2 · Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4)
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
2 · GHS02,GHS06,GHS08
Signal word
Danger
Hazard statements
225 · H225-H301+H311+H331-H370
Precautionary statements
210 · P210-P260-P280-P301+P310-P311
target organs
Eyes,Central nervous system
Hazard Codes
F,T
Risk Statements
11 · 11-23/24/25-39/23/24/25
Safety Statements
7 · 7-16-36/37-45
RIDADR
3249 · 3249
WGK Germany
1 · 1
HazardClass
6.1 · 6.1(b)
PackingGroup
III
Storage Class
3 · 3 - Flammable liquids
Hazard Classifications
3 DermalAcute · Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
REACH Registrations
Active
· 1 item

In clinical trials, flecainide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, flecainide has only rarely been linked to cases of clinically apparent liver injury. The typical presentation is with a cholestatic hepatitis arising within 1 to 6 weeks of starting flecainide. In addition, instances of acute hepatic injury arising within 1 to 3 days of starting flecainide with marked, but short lived elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase have been published, but may actually represent acute worsening of congestive heart failure and ischemic hepatitis due to the proarrhythmic effects of flecainide. In all instances, the liver injury was self limited. Immunoallergic and autoimmune features were not present.

Adverse EffectsCardiac Toxicity
Exposure RoutesIngestion (MSDS, A308). Nearly complete following oral administration.
Toxicity Summary · 2 items

Signs and Symptoms of Overdose

Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.

Signs and Symptoms · 1 item

Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

flecainide

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 50-498 mg/kg (Oral, Rat) (A308)

Safety data

wgk
1
ridadr
3249
risk_code
11-23/24/25-39/23/24/25
Signal word
Danger
Symbol(GHS)
GHS02,GHS06,GHS08
hazard_code
F,T
safety_code
7-16-36/37-45
hazard_class
6.1(b)
Storage Class
3 - Flammable liquids
packing_group
III
target organs
Eyes,Central nervous system
Hazard statements
H225-H301+H311+H331-H370
REACH Registrations
Active
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
Precautionary statements
P210-P260-P280-P301+P310-P311
FDA Pharmacological Classification · 4 items

K94FTS1806

FLECAINIDE

Established Pharmacologic Class [EPC] - Antiarrhythmic

Flecainide is an Antiarrhythmic.

MeSH Pharmacological Classification · 2 items

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 4 items

Oral flecainide has a Tmax of 3-4h and a bioavialability of 90%. Taking flecainide with food or aluminum hydroxide antacids do not significantly affect the absorption of flecainide.

Approximately 86% of a single oral dose is eliminated in the urine, with 42% as unchanged flecainide and 14% as meta-O-dealkylated flecainide, a similar amount of the meta-O-dealkylated lactam of flecainide, approximately 3% as an unidentified acid metabolite, and <1% as 2 other unknown metabolites. 5% is eliminated in the feces.

The average volume of distribution in 8 male subjects is 5.0-13.4L/kg.

The average clearance of intravenous flecainide is 4.6-12.1mL/min/kg in 8 male subjects. For oral flecainide, the clearance was 4-20mL/min/kg.

Cellular LocationsMembrane
Metabolite PathwaysFlecainide Action Pathway

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): >2500

Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin (A308).

Use ClassificationPharmaceuticals
Applications · 3 items

DescriptionFrom the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.

UsesFlecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.

UsesFlecainide is an antiarrhythmic (class IC).

Upstream & downstream products

Upstream raw materials

2-PIPERIDYLMETHYLAMINEDesiccant2,5-Dihydroxybenzoic acid2-PicolylamineMagnesium sulfateHydrochloric acid2,5-Bis(2,2,2-trifluoroethoxy)benzoic acid2,2,2-TRIFLUOROETHYL 2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZOATEMETHYL 2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZOATE
Additional notes · 1 item

DefinitionChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prev nt and treat tachyarrhythmia (abnormal fast rhythm of the heart).